EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Clinical trial NCT07617805 · RECRUITING

Trial details

NCT number: NCT07617805
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Biomarker-positive EGFR/HER2- Expressing HNSCC

Start date: 2026-03-02
Primary completion: 2027-03-14
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.